8-K: Ekso Bionics Announces Preliminary Record Revenue for Fourth Quarter 2024

Ekso Bionics anticipates record revenue for Q4 2024, with preliminary results showing revenue between $5.0 and $5.1 million.

Summary

• Ekso Bionics has released preliminary financial results for the fourth quarter of 2024.
• The company estimates total revenue to be between $5.0 million and $5.1 million, which would be a record for the company.
• This compares to $4.8 million in revenue for the fourth quarter of 2023.
• The company's cash balance is estimated to be $6.5 million as of December 31, 2024, down from $8.6 million at the end of 2023.
• Net cash used in operations for the fourth quarter of 2024 is estimated at $1.5 million, compared to $1.6 million for the same period in 2023.
• These results are preliminary and unaudited, and may be subject to adjustments during the finalization of the financial statements.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to record revenue, but tempered by the decrease in cash and ongoing cash burn. The company is making progress but faces financial challenges.

Positives

• The company is reporting record preliminary revenue for the fourth quarter of 2024.
• There was a slight improvement in net cash used in operations compared to the same period last year.
• The company has made progress with CMS reimbursement for the Ekso Indego Personal device.

Negatives

• The company's cash balance has decreased significantly year-over-year.
• The company is still using cash in operations, although at a slightly reduced rate compared to the same period last year.

Risks

• The preliminary financial results are unaudited and subject to adjustments.
• The company's ability to achieve future reimbursements from CMS is not guaranteed.
• The company faces risks related to obtaining additional insurance coverage beyond CMS.
• There are risks associated with the development and market acceptance of the company's products.
• The company's ability to obtain adequate financing to fund and grow the company's operations is a risk.
• The company faces competition and supply chain risks.

Future Outlook

The company expects to report complete fourth quarter and full year 2024 financial results during the first week of March 2025 and is focused on building upon their growing CMS claim pipeline and bolstering demand for their EksoNR device.

Management Comments

• Scott Davis, the company's CEO, stated that they made significant progress in 2024, highlighted by initial CMS reimbursement for their Ekso Indego Personal device.
• The CEO also mentioned that they remain focused on building upon their growing CMS claim pipeline and continuing to bolster demand for their flagship EksoNR device.

Industry Context

Ekso Bionics operates in the exoskeleton technology sector, which is focused on developing wearable robots for medical and industrial applications. The company's focus on CMS reimbursement is a key factor for growth in the medical device market, and the company is competing with other companies in the space.

Comparison to Industry Standards

• While the document does not provide specific comparisons to industry standards, the company's focus on CMS reimbursement is a common strategy for medical device companies in the US.
• Companies like ReWalk Robotics and Cyberdyne also operate in the exoskeleton space, but the document does not provide enough information to make a direct comparison of financial performance.
• The revenue growth from $4.8 million to a range of $5.0 to $5.1 million is a positive sign, but the cash burn of $1.5 million in the quarter is a concern that needs to be monitored.

Stakeholder Impact

• Shareholders may react positively to the record revenue, but negatively to the decrease in cash.
• Employees may be encouraged by the company's growth, but concerned about the financial situation.
• Customers may be encouraged by the company's progress and the availability of their products.
• Suppliers may be concerned about the company's cash position.
• Creditors may be concerned about the company's cash burn and decreasing cash balance.

Next Steps

• The company will finalize its financial statements for the quarter ended December 31, 2024.
• The company expects to report complete fourth quarter and full year 2024 financial results during the first week of March 2025.

Key Dates

Keywords

exoskeleton, medical devices, rehabilitation, wearable robots, CMS reimbursement, revenue, financial results, Ekso Bionics, EKSO, cash flow